MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells

Although many epidermal growth factor receptor (EGFR)-mutated lung cancer patients initially benefit from the EGFR-inhibitor erlotinib, all acquire resistance. So far, several mechanisms implicated in resistance have been identified, but the existence of multiple resistance mechanisms in parallel ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Jakobsen, K R, Demuth, C, Madsen, A T, Hussmann, D, Vad-Nielsen, J, Nielsen, A L, Sorensen, B S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520494/
https://www.ncbi.nlm.nih.gov/pubmed/28368392
http://dx.doi.org/10.1038/oncsis.2017.17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520494/
https://www.ncbi.nlm.nih.gov/pubmed/28368392
http://dx.doi.org/10.1038/oncsis.2017.17

Ejemplares similares